McKesson to pay $150M in prescription drug probe
Drug distributor McKesson will pay a record $150 million civil penalty for alleged violations of the Controlled Substances Act, the Justice Department announced today. The settlement also imposes new and enhanced compliance obligations, as well as an independent monitor—the first independent monitor of its kind in a CSA civil penalty ...
Related articles
-
ArticleReckitt Benckiser’s record $1.4B opioid settlement a warning for drug companies
Reckitt Benckiser Group will pay $1.4 billion to resolve a long-running federal investigation concerning the sales and marketing of the opioid addiction treatment drug Suboxone.
-
ArticleNursing home chain and former CEO pay $146M each for federal health fraud
A New Jersey and Midwest nursing home chain, and its former chief executive, must pay more than $146 million each for extensive health care fraud for engaging in widespread fraud related to Medicare and Medicaid.
-
ArticleHorizon Blue Cross Blue Shield pays $100M to settle state false claims allegations
Horizon Blue Cross Blue Shield of New Jersey has agreed to pay $100 million to settle allegations that its 2020 contract with the state was fraudulent, according the state’s Attorney General.